compareglp1.Reviews →

Compare GLP-1 medications & providers

Eight FDA-approved GLP-1 medications and the leading compounded-GLP-1 telehealth providers, side by side. We compare apples to apples — within the segment.

GLP-1 medications

BrandGenericTypeRouteFrequencyIndicationAvg lossMaker
OzempicSemaglutideGLP-1 RAInjectionOnce weeklyType 2 Diabetes6–10%Novo Nordisk
WegovySemaglutideGLP-1 RAInjectionOnce weeklyWeight Management~15%Novo Nordisk
MounjaroTirzepatideDual GIP/GLP-1 RAInjectionOnce weeklyType 2 Diabetes~15%Eli Lilly
ZepboundTirzepatideDual GIP/GLP-1 RAInjectionOnce weeklyWeight Management~21%Eli Lilly
RybelsusSemaglutideGLP-1 RAOralDailyType 2 Diabetes3–5%Novo Nordisk
SaxendaLiraglutideGLP-1 RAInjectionDailyWeight Management5–8%Novo Nordisk
VictozaLiraglutideGLP-1 RAInjectionDailyType 2 Diabetes3–6%Novo Nordisk
TrulicityDulaglutideGLP-1 RAInjectionOnce weeklyType 2 Diabetes3–6%Eli Lilly

Average weight loss figures reflect clinical trial averages at therapeutic doses; individual outcomes vary.

Compounded GLP-1 providers — segment comparison

We compare the leading compounded semaglutide and tirzepatide telehealth providers head-to-head on the protections that affect patients most.

ProviderScoreTransparent pricingNo subscriptionMoney-backClinical eval includedU.S. support
FMmedsEditor's Pick4.9✅ Published✅ Included✅ 100% U.S.
Henry Meds3.2⚠️ Limited⚠️ Add-on⚠️ Mixed
Mochi Health2.7⚠️ Limited⚠️ Add-on⚠️ Mixed
Fridays3.3⚠️ Limited⚠️ Add-on⚠️ Mixed
CoreAge Rx2.4⚠️ Limited⚠️ Add-on⚠️ Mixed

Comparison reflects our editorial review of publicly disclosed terms and pricing within the compounded GLP-1 telehealth segment. See methodology.

Ready to choose a provider?

Start with the only provider in the segment that combines all four protections.

See plans